AbbVie Inc. · ABBV · FY2025 Q3 · Calendar Q4 2025

AbbVie: Immunology growth offsets biosimilar and pricing risks

The latest analysis supports a constructive but qualified view: resilient immunology and neuroscience growth, raised guidance and pipeline progress strengthen the growth case, while biosimilar erosion, pricing changes and aesthetics softness remain material counterweights.

Reported Before market openNYSEHealthcare $462.53B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $1.86 Consensus $1.77
EPS surprise +5.1% Reported versus consensus
Reported revenue $15.78B Consensus $15.59B
Revenue surprise +1.2% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move -4.5% Event window
SPY move +0.3% Same window
Abnormal move -4.8% Stock minus SPY
Volume 2.0× Versus trailing sessions
Subsequent drift +3.2% Up to 20 sessions
ABBVSPY benchmark

Ask FN2 about ABBV FY2025 Q3

Transcript, numbers and history already loaded
Why did ABBV fall 4.5% after beating EPS estimates in FY2025 Q3?What changed in ABBV's guidance and outlook in FY2025 Q3?Give me the bull and bear case for ABBV after FY2025 Q3 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Relative to the prior quarter, the analysis continues to show raised guidance and strong Skyrizi/Rinvoq momentum, while adding emphasis on tavapadon, PVEK, Temab-A and manufacturing expansion. The risk set remains centered on biosimilars, pricing and aesthetics demand.

Guidance delta

Management raised full-year 2025 guidance, continuing the prior quarter's positive guidance trajectory.

Key takeaways

  • Current-quarter analysis points to an EPS and revenue beat, led by Skyrizi and Rinvoq.
  • Immunology, neuroscience and aesthetics were identified as key growth areas.
  • Management highlighted pipeline progress in tavapadon, PVEK, Temab-A and Rinvoq indications.
  • Humira biosimilar erosion remains a pressure, while pricing and reimbursement changes add uncertainty.

Management priorities

  • Advance Skyrizi and Rinvoq
  • Progress tavapadon, PVEK, Temab-A and Rinvoq indications
  • Expand manufacturing capacity and maintain capital investment
  • Develop neuroscience, oncology and obesity assets

Follow ABBV with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ABBV EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q4 '23 estimate $2.76 Q4 '23 actual $2.79, beat Q1 '24 estimate $2.26 Q1 '24 actual $2.31, beat Q2 '24 estimate $2.57 Q2 '24 actual $2.65, beat Q3 '24 estimate $2.92 Q3 '24 actual $3.00, beat Q2 '25 estimate $2.88 Q2 '25 actual $2.97, beat Q3 '25 estimate $1.77 Q3 '25 actual $1.86, beat Q4 '25 estimate $2.65 Q4 '25 actual $2.71, beat Q1 '26 estimate $2.59 Q1 '26 actual $2.65, beat Q2 '26 estimate $3.61 Q2 '26 actual $3.65, beat Q3 '26 estimate $3.86 Q4 '26 estimate $4.00 Q1 '27 estimate $3.32
Show less

Analyst Consensus ?

ConsensusBuy43 ratings
Bullish3172.1%
Neutral1125.6%
Bearish12.3%

Analyst 52W Price Targets

$259.93Current
$127Low
$214.81Average
$315High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 1, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
HSBC Buy BuyMaintainSep 10, 2026
Piper Sandler Overweight OverweightMaintainAug 20, 2026
Wells Fargo Overweight OverweightMaintainAug 17, 2026
Wolfe Research Outperform Peer PerformUpgradeAug 13, 2026
BNP Paribas Neutral NeutralMaintainAug 11, 2026
Show 38 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $259.93. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
HSBCRajesh Kumar$315$250.98 +21.2%Sep 10, 2026
Piper SandlerAnalyst unavailable$303$265.97 +16.6%Aug 20, 2026
Wells FargoAnalyst unavailable$300$249.45 +15.4%Aug 17, 2026
Wolfe ResearchAlexandria Hammond$300$248.66 +15.4%Aug 13, 2026
GuggenheimAnalyst unavailable$288$245.08 +10.8%Aug 4, 2026
See 90 more

Track every rating change on ABBV the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism.…

Historical context

All ABBV earnings
-2.5%FY2026 Q2 · Calendar Q3 2026+3.1%FY2026 Q1 · Calendar Q2 2026

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
COO The Cooper Companies, Inc. FY2026 Q3 · Calendar Q3 2026 +2.7% -14.7% CooperCompanies beats expectations as inventory reduction weighs on vision revenue
MDT Medtronic plc FY2027 Q1 · Calendar Q3 2026 +4.3% +1.5% Medtronic raises FY27 outlook as growth broadens across platforms

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the ABBV recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
  3. Polygon adjusted daily market bars · 2026-10-01T20:16:11.791151+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-01T20:16:11.788000+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-01. For educational purposes only; not investment advice.